3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Glioma
2
Glioblastoma
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Resectable Lung Non-Small Cell Carcinoma
1
Radiation Injuries
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lung Neoplasms
1
Gastroesophageal Junction Adenocarcinoma
1
Frailty
1
Chordoma
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Astrocytoma
1
Interventions
Nivolumab
3
palbociclib
2
Ipilimumab
2
Imatinib Mesylate
2
relatlimab
1
pembrolizumab
1
camrelizumab
1
apatinib
1
Specimen Handling
1
Radiotherapy
1
Radiation
1
Protons
1
Proton Therapy
1
Pemetrexed
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Disulfides
1
Dasatinib
1
Cetuximab
1
CTLA-4 Antigen
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Chordoma
×
Protons
×
Clear all
NCT01811394
2023-12-06
ISAC
Heidelberg University
Phase 2
Unknown
100 enrolled